Dr. Hasan Jafri has been involved in the design and conduct of multiple Phase 1‐4 clinical studies to assess novel small and large molecules against bacterial, viral and fungal pathogens. Prior to joining MedImmune, Dr. Jafri served as a professor in pediatric infectious diseases and clinical science research at the University of Texas Southwestern Medical Center at Dallas. He was the director of the Pediatric Infectious Diseases fellowship program, Chief of Division of Clinical Pharmacology, and director of the NICHD Pediatric Pharmacology Research Unit. He has also served at the US Center for Disease Control and Prevention (CDC). He has over 20 years of experience in clinical practice and research, especially in the area of serious healthcare associated and community acquired infections, respiratory viral infections and fungal infections (in immunocompromised and immunocompetent hosts), and biomarker and translational research. He has authored over 60 peer reviewed journal articles. Dr. Jafri serves as the industry lead on the European Commission’s IMI COMBACTE programs involving development of MedImmune/AstraZeneca’s novel antibacterial monoclonal antibodies MEDI4893 and MEDI3902, and serves as the overall Coordinator of the COMBACTE-NET and COMBACTE-MAGNET consortia.
Dr. Jafri will be speaking at World Anti-Microbial Resistance Congress USA 2016. The session will be entitled ‘IMI-COMBACTE, developing novel antibacterials in a public private partnership: accomplishments and vision’ and will cover developing novel trial designs to deliver safety, pharmacology, and proof of efficacy data for novel agents, using novel molecules to prevent serious infections and the spread of antimicrobial resistance, and contribution towards global efforts against antimicrobial resistant infections. To hear from Dr. Jafri and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC.